

CORCEPT THERAPEUTICS INC

Form 8-K

December 27, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report: December 22, 2010**  
**(Date of earliest event reported)**

**Corcept Therapeutics Incorporated**  
**(Exact name of registrant as specified in its charter)**

**DE**  
**(State or other jurisdiction**  
**of incorporation) 000-50679**  
**(Commission File Number) 77-0487658**

**(IRS Employer**  
**Identification Number)**  
**149 Commonwealth Drive, Menlo Park, CA**  
**(Address of principal executive offices) 94025**  
**(Zip Code)**  
**650-327-3270**  
**(Registrant's telephone number, including area code)**

**Not Applicable**  
**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

### **Item 7.01. Regulation FD Disclosure**

On December 22, 2010 we issued a press release announcing positive top-line results from our Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the response of two patient groups to CORLUX treatment: one included patients who were glucose intolerant and one included patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved for both groups: with 60% responding in the glucose intolerant group and 43% in the hypertensive group. An initial review of safety data indicates that CORLUX was well tolerated by Cushing's Syndrome patients in this Phase 3 study.

The information in this Item 7.01 and the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K are being "furnished" pursuant to Item 7.01 and shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that Section, or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 and the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

### **Item 8.01. Other Events**

On December 22, 2010 we issued a press release announcing positive top-line results from our Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the response of two patient groups to CORLUX treatment: one included patients who were glucose intolerant and one included patients who were hypertensive. Statistically significant improvement in the primary endpoint was achieved for both groups: with 60% responding in the glucose intolerant group and 43% in the hypertensive group. An initial review of safety data indicates that CORLUX was well tolerated by Cushing's Syndrome patients in this Phase 3 study.

### **Item 9.01. Financial Statements and Exhibits**

#### **(a) Financial statements:**

None

#### **(b) Pro forma financial information:**

None

#### **(c) Shell company transactions:**

None

#### **(d) Exhibits**

99.1 Press Release of Corcept Therapeutics Incorporated dated December 22, 2010

---

### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 27, 2010

**CORCEPT THERAPEUTICS INCORPORATED**

By: /s/ Caroline M. Loewy  
Caroline M. Loewy  
*Chief Financial Officer*

---

**Exhibit Index** **Exhibit No.** **Description** 99.1 Press Release of Corcept Therapeutics Incorporated dated December 22, 2010